Protalix Biotherapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.74
- Today's High:
- $1.85
- Open Price:
- $1.74
- 52W Low:
- $1
- 52W High:
- $3.55
- Prev. Close:
- $1.75
- Volume:
- 375029
Company Statistics
- Market Cap.:
- $125.27 million
- Book Value:
- 0.545
- Revenue TTM:
- $67.46 million
- Operating Margin TTM:
- 18.29%
- Gross Profit TTM:
- $28.05 million
- Profit Margin:
- 13.19%
- Return on Assets TTM:
- 10.35%
- Return on Equity TTM:
- 61.15%
Company Profile
Protalix Biotherapeutics Inc had its IPO on 1998-05-15 under the ticker symbol PLX.
The company operates in the Healthcare sector and Biotechnology industry. Protalix Biotherapeutics Inc has a staff strength of 193 employees.
Stock update
Shares of Protalix Biotherapeutics Inc opened at $1.74 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.74 - $1.85, and closed at $1.8.
This is a +2.86% increase from the previous day's closing price.
A total volume of 375,029 shares were traded at the close of the day’s session.
In the last one week, shares of Protalix Biotherapeutics Inc have slipped by -9.09%.
Protalix Biotherapeutics Inc's Key Ratios
Protalix Biotherapeutics Inc has a market cap of $125.27 million, indicating a price to book ratio of 224.575 and a price to sales ratio of 1.2355.
In the last 12-months Protalix Biotherapeutics Inc’s revenue was $67.46 million with a gross profit of $28.05 million and an EBITDA of $13.46 million. The EBITDA ratio measures Protalix Biotherapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Protalix Biotherapeutics Inc’s operating margin was 18.29% while its return on assets stood at 10.35% with a return of equity of 61.15%.
In Q2, Protalix Biotherapeutics Inc’s quarterly earnings growth was a negative -39.2% while revenue growth was a positive 300.7%.
Protalix Biotherapeutics Inc’s PE and PEG Ratio
- Forward PE
- 111.1111
- Trailing PE
- 58.3333
- PEG
- -0.1
Its diluted EPS in the last 12-months stands at $0.03 per share while it has a forward price to earnings multiple of 111.1111 and a PEG multiple of -0.1. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Protalix Biotherapeutics Inc’s profitability.
Protalix Biotherapeutics Inc stock is trading at a EV to sales ratio of 1.4947 and a EV to EBITDA ratio of -5.0799. Its price to sales ratio in the trailing 12-months stood at 1.2355.
Protalix Biotherapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $88.42 million
- Total Liabilities
- $23.11 million
- Operating Cash Flow
- $4.51 million
- Capital Expenditure
- $204000
- Dividend Payout Ratio
- 0%
Protalix Biotherapeutics Inc ended 2024 with $88.42 million in total assets and $0 in total liabilities. Its intangible assets were valued at $88.42 million while shareholder equity stood at $39.00 million.
Protalix Biotherapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $23.11 million in other current liabilities, 292.00 in common stock, $-3748109.00 in retained earnings and $0 in goodwill. Its cash balance stood at $48.18 million and cash and short-term investments were $48.18 million. The company’s total short-term debt was $1,260,000 while long-term debt stood at $20.13 million.
Protalix Biotherapeutics Inc’s total current assets stands at $73.58 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $4.05 million compared to accounts payable of $3.30 million and inventory worth $19.64 million.
In 2024, Protalix Biotherapeutics Inc's operating cash flow was $4.51 million while its capital expenditure stood at $204000.
Comparatively, Protalix Biotherapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.8
- 52-Week High
- $3.55
- 52-Week Low
- $1
- Analyst Target Price
- $16
Protalix Biotherapeutics Inc stock is currently trading at $1.8 per share. It touched a 52-week high of $3.55 and a 52-week low of $3.55. Analysts tracking the stock have a 12-month average target price of $16.
Its 50-day moving average was $1.82 and 200-day moving average was $1.89 The short ratio stood at 5.66 indicating a short percent outstanding of 0%.
Around 954.8% of the company’s stock are held by insiders while 669.4% are held by institutions.
Frequently Asked Questions About Protalix Biotherapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.